AFFILIATIONS
1 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
2 ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
3 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
4 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
5 ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
6 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
7 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
8 Immunoanalytic, Helmholtz Zentrum München, Munich, Germany
9 Immunoanalytic, Helmholtz Zentrum München, Munich, Germany
10 Department of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
11 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
12 Department of Anthropology and Human Genomics, Ludwig-Maximilians-Universität München, Munich, Germany
13 Department of Anthropology and Human Genomics, Ludwig-Maximilians-Universität München, Munich, Germany
14 Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, ELLF Laboratory, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
ABSTRACT
Crosstalk between cancer cells and microenvironment has gained significant momentum, offering key insights for the development of therapeutic strategies. Irradiation, which is used as a conditioning regimen for BM transplantation (BMT) and as a strategy for better engraftment in murine AML models, is one factor that alters the bone marrow (BM) niche. However, little is known about the characteristics of AML in an irradiated tumor microenvironment (TME) and its role in therapy response. We employed an epigenetic therapy, inhibiting the lysine-specific demethylase 1 (LSD1i), which has potent antileukemic effect in the MLL-rearranged AML (MLL-AF9+). LSD1 is known to modulate the TME regulating the activity of immune cells (reviewed by Mamum et al., 2023). Here we investigated how the combination of irradiation and LSD1i affects the microenvironment and leukemic growth.
The murine MLL-AF9+ AML model was used. Recipient mice underwent irradiation (IRR) before transplantation of leukemic cells and were compared to non-irradiated leukemic mice. Cocultures of mesenchymal stromal cells (MSC) with AML cells and RNAseq were performed, colony forming and cytokine release assays (23-plex immunoassay) were performed.
In irradiated mice, AML developed after a shorter latency in comparison to non-irradiated recipients. Notably, irradiated mice did not respond to LSD1i and showed unchanged leukemic burden compared to untreated non-irradiated and irradiated mice (83.8% BM engraftment in untreated vs. 87.6% in treated irradiated mice, p=0.63). To understand how irradiation of the microenvironment might induce resistance of AML cells to LSD1i we analyzed non-irradiated and irradiated (2-20Gy) LSD1i-exposed murine stromal cells (primary MSC from compact bone and BM, OP9 and S17). The proliferation of MSC was inversely proportional to the IRR dose while LSD1i (0.5 μM) did not significantly affect cell growth. IRR affected the differentiation potential of MSC (increased adipocytic marker), LSD1i±IRR increased osteocalcin and osteopontin. RNAseq analysis of treated MSC revealed 328 differentially expressed genes upon IRR, 438 upon LSD1i, and 606 upon IRR+LSD1i, in comparison to the control untreated/non-irradiated MSC. IRR+LSD1i uniquely changed the expression of 276 genes, , which was also seen by PCA analysis. While IRR alone depleted the expression of inflammation-related genes, LSD1i treatment affected several metabolic pathways. Moreover, the combination of IRR+LSD1i uniquely influenced proliferation and stemness-related genes. MSC cells released less CCL2, CCL5, CXCL1 and IL6 upon IRR+LSD1i in comparison to the single treatments.
To assess the effect of these changes on AML cells, cocultures with supernatant (SN) of irradiated MSC or transwell assays were performed. The SN from untreated MSC decreased the response of AML cells to LSD1i with persistence of blasts cells independently from IRR. By trend, we observed an enrichment of more immature, leukemic stem cell-associated markers (ckit+Mac1+) on AML cells exposed to SN from MSC exposed to IRR+LSD1i, suggesting a possible role of IRR in mediating resistance to LSD1i treatment as observed in vivo. Cytokine release assay from cocultures revealed that only AML cells exposed to SN from irradiated MSC exhibited significantly higher CCL5 level. In cocultures with direct-contact, TNF-a, CSF2, CXCL1, CCL2 were decreased only if MSC underwent IRR+LSD1i, suggesting a unique interplay between irradiation and LSD1i in MSC, and cell-to-cell interactions between AML and MSC.
In conclusion, irradiation of recipient mice before leukemia induction in a syngeneic setting leads to a shorter latency until onset of AML. The irradiation also mediates resistance to the antileukemic treatment with LSD1i in vivo. We reported changes induced by IRR+LSD1i on stroma cells in vitro, such as a unique transcriptional signature and cytokines release profile. AML cells treated in vitro in the presence of irradiated stroma were less sensitive to LSD1i and changed their chemokine release profile. We hypothesize that irradiation of the microenvironment causes resistance to the epigenetic therapy. The resistance in vitro was less strong as observed in vivo, suggesting that additional factors present in the microenvironment, such as other immune cells, might modulate the therapy response. Identifying the microenvironment-derived resistance mechanisms should help to design new therapeutic concepts for AML patients.
DISCLOSURES
Monica Cusan, MD: No relevant conflicts of interest to declare.